The Prevalence of extraintestinal manifestations in Inflammatory Bowel Disease
DOI:
https://doi.org/10.12775/JEHS.2024.58.007Keywords
IBD, drugs used in IBD, Crohn disease, ulcerative colitis, psc, psc and ibdAbstract
INTRODUCTION: The term inflammatory bowel disease (IBD) refers to a chronic inflammatory disease of the gastrointestinal tract of unclear pathogenesis. IBD consists of ulcerative colitis (UC) and Crohn's disease (CD). The two most common manifestations of the disorder, both have a chronic course with episodes of acute activity. Their underlying pathogenesis and symptoms, however, are quite distinct. IBD has a multiple factor etiology involving genetics, immunological dysregulation and dysbiosis of the intestinal microbiome. The resulting chronic inflammation of the entire body is the cause of the symptoms and signs of the condition. Extraintestinal manifestations (EIM) occur in 5% to 50% of IBD patients over the course of their lifetime.
PURPOSE: The aim of the study is to present the current state of knowledge about the prevalence of extraintestinal manifestations in Inflammatory Bowel Disease.
MATERIALS AND METHOD: The available literature in PubMed was reviewed to write the article, using the keywords ,,inflammatory bowel disease”, ,,Crohn’s disease”, ,,
ulcerative colitis”, ,,extraintestinal manifestations IBD”.
CONCLUSION: Extraintestinal manifestations are evidence that IBD is not only confined to the intestine, these may involve many different organs other than the gut and may be more devastating than the IBD. Screening for EIM in these patients and prompt adequate treatment are essential. To adequately manage EIM and improve the quality of life of our patients, appropriate treatment regimens and therapies are required in a multidisciplinary team approach. Due to the lack of available dedicated diagnostic biomarkers for EIM, consideration of concomitant extraintestinal conditions in patients with inflammatory bowel disease might help in the selection and management of them. Clinicians caring for patients with IBD must be aware of these various systemic manifestations, as failure to diagnose and treat them early can result in significant morbidity.
References
The epidemiology and risk factors of inflammatory bowel disease. Ye Y, Pang Z, Chen W, Ju S, Zhou C.
Malik TF, Aurelio DM. Extraintestinal Manifestations of Inflammatory Bowel Disease. 2023 Mar 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 33760556.
Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015 Aug;21(8):1982-92
Satsangi J, Grootscholten C, Holt H, Jewell DP. Clinical patterns of familial inflammatory bowel disease. Gut. 1996 May;38(5):738-41.
Roussomoustakaki M, Satsangi J, Welsh K, Louis E, Fanning G, Targan S, Landers C, Jewell DP. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology. 1997 Jun;112(6):1845-53.
Mallas EG, Mackintosh P, Asquith P, Cooke WT. Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27). Gut. 1976 Nov;17(11):906-10.
Bhagat S, Das KM. A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. Gastroenterology. 1994 Jul;107(1):103-8.
Khan I, Ullah N, Zha L, Bai Y, Khan A, Zhao T, Che T, Zhang C. Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. Pathogens. 2019 Aug 13;8(3)
Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013 Oct;10(10):585-95.
Greuter T, Bertoldo F, Rechner R, Straumann A, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Rogler G, Safroneeva E, Ali RAR, Braegger C, Heyland K, Mueller P, Nydegger A, Petit LM, Schibli S, Furlano RI, Spalinger J, Schäppi M, Zamora S, Froehlich F, Herzog D, Schoepfer AM, Vavricka SR., Swiss IBD Cohort Study Group. Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment. J Pediatr Gastroenterol Nutr. 2017 Aug;65(2):200-206
Feagins L. A., Cryer B. L. Do non-steroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease? Digestive Diseases and Sciences. 2010;55(2):226–232. doi: 10.1007/s10620-009-1042-7.
Li JX, Chiang CC, Chen SN, Lin JM, Tsai YY. The Prevalence of Ocular Extra-Intestinal Manifestations in Adults Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2022 Nov 25;19(23):15683. doi: 10.3390/ijerph192315683. PMID: 36497759; PMCID: PMC9737331.
Licona Vera E, Betancur Vasquez C, Peinado Acevedo JS, Rivera Bustamante T, Martinez Redondo JM. Ocular Manifestations of Inflammatory Bowel Disease. Cureus. 2023 Jun 12;15(6):e40299. doi: 10.7759/cureus.40299. PMID: 37448411; PMCID: PMC10337643.
Lee DH, Han JY, Park JJ, Cheon JH, Kim M. Ophthalmologic Manifestation of Inflammatory Bowel Disease: A Review. Korean J Gastroenterol. 2019 May 25;73(5):269-275. doi: 10.4166/kjg.2019.73.5.269. PMID: 31132833.
Pytrus W, Akutko K, Pytrus T, Turno-Kręcicka A. A Review of Ophthalmic Complications in Inflammatory Bowel Diseases. J Clin Med. 2022 Dec 15;11(24):7457. doi: 10.3390/jcm11247457. PMID: 36556071; PMCID: PMC9781961.
Troncoso LL, Biancardi AL, de Moraes HV Jr, Zaltman C. Ophthalmic manifestations in patients with inflammatory bowel disease: A review. World J Gastroenterol. 2017 Aug 28;23(32):5836-5848. doi: 10.3748/wjg.v23.i32.5836. PMID: 28932076; PMCID: PMC5583569.
Kim YS, Lee J. [Musculoskeletal Manifestation in Inflammatory Bowel Disease]. Korean J Gastroenterol. 2019 May 25;73(5):276-284. Korean. doi: 10.4166/kjg.2019.73.5.276. PMID: 31132834.
Ali A, Schmidt M, Piskin D, Crowley E, Berard R. Epidemiology of Musculoskeletal Manifestations in Pediatric Inflammatory Bowel Disease: A Systematic Review. ACR Open Rheumatol. 2022 Jun;4(6):547-554. doi: 10.1002/acr2.11431. Epub 2022 Mar 29. PMID: 35352509; PMCID: PMC9190227.
Steell L, Gray SR, Russell RK, MacDonald J, Seenan JP, Wong SC, Gaya DR. Pathogenesis of Musculoskeletal Deficits in Children and Adults with Inflammatory Bowel Disease. Nutrients. 2021 Aug 23;13(8):2899. doi: 10.3390/nu13082899. PMID: 34445056; PMCID: PMC8398806.
Sheth T, Pitchumoni CS, Das KM. Management of Musculoskeletal Manifestations in Inflammatory Bowel Disease. Gastroenterol Res Pract. 2015;2015:387891. doi: 10.1155/2015/387891. Epub 2015 Jun 10. PMID: 26170832; PMCID: PMC4478299.
Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, Gasbarrini G, Gasbarrini A. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005 Dec 14;11(46):7227-36.
Charatcharoenwitthaya P, Angulo P, Enders FB, Lindor KD. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. Hepatology. 2008 Jan;47(1):133-42. doi: 10.1002/hep.21960. PMID: 17992695.
Yarur AJ, Czul F, Levy C. Hepatobiliary manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2014 Sep;20(9):1655-67.
Greuter T, Vavricka SR. Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis. Greuter T, Vavricka SR. Expert Rev Gastroenterol Hepatol. 2019;13:307–317.
He R, Zhao S, Cui M, Chen Y, Ma J, Li J, Wang X. Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations. Front Immunol. 2023 Oct 26;14:1234535. doi: 10.3389/fimmu.2023.1234535. PMID: 37954590; PMCID: PMC10637386.
Antonelli E, Bassotti G, Tramontana M, Hansel K, Stingeni L, Ardizzone S, Genovese G, Marzano AV, Maconi G. Dermatological Manifestations in Inflammatory Bowel Diseases. J Clin Med. 2021 Jan 19;10(2):364. doi: 10.3390/jcm10020364. PMID: 33477990; PMCID: PMC7835974.
Alvarez-Payares JC, Ramírez-Urrea S, Correa-Parra L, Salazar-Uribe D, Velásquez-López M. Mucocutaneous Manifestations of Inflammatory Bowel Disease. Cureus. 2021 Aug 15;13(8):e17191. doi: 10.7759/cureus.17191. PMID: 34548985; PMCID: PMC8439267.
Ungureanu L, Cosgarea R, Alexandru Badea M, Florentina Vasilovici A, Cosgarea I, Corina Șenilă S. Cutaneous manifestations in inflammatory bowel disease (Review). Exp Ther Med. 2020 Jul;20(1):31-37. doi: 10.3892/etm.2019.8321. Epub 2019 Dec 12. PMID: 32508989; PMCID: PMC7271697.
Keyal U, Liu Y, Bhatta AK. Dermatologic manifestations of inflammatory bowel disease: a review. Discov Med. 2018 May;25(139):225-233. PMID: 29906405.
Rosen MJ, Dhawan A, Saeed SA. Inflammatory Bowel Disease in Children and Adolescents. JAMA Pediatr. 2015 Nov;169(11):1053-60. doi: 10.1001/jamapediatrics.2015.1982. PMID: 26414706; PMCID: PMC4702263.
Greuter T, Rieder F, Kucharzik T, Peyrin-Biroulet L, Schoepfer AM, Rubin DT, Vavricka SR. Emerging treatment options for extraintestinal manifestations in IBD. Gut. 2021 Apr;70(4):796-802. doi: 10.1136/gutjnl-2020-322129. Epub 2020 Aug 26. PMID: 32847845; PMCID: PMC9014274.
Fragoulis GE, Liava C, Daoussis D, Akriviadis E, Garyfallos A, Dimitroulas T. Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment. World J Gastroenterol. 2019 May 14;25(18):2162-2176. doi: 10.3748/wjg.v25.i18.2162. PMID: 31143068; PMCID: PMC6526158.
Moazzami B, Moazzami K, Rezaei N. Early onset inflammatory bowel disease: manifestations, genetics and diagnosis. Turk J Pediatr. 2019;61(5):637-647. doi: 10.24953/turkjped.2019.05.001. PMID: 32104994.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Aleksandra Madej, Hanna Senat, Patrycja Grabowska, Patrycja Bolla, Aleksandra Senat, Zuzanna Marczyńska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 299
Number of citations: 0
